The growing impact of micro/nanomaterial‐based systems in precision oncology: translating “multiomics” technologies

The field of precision oncology is rapidly progressing toward integrated “multiomics” analysis of multiple molecular species (such as DNA, RNA, or proteins) to provide a more complete profile of tumor heterogeneity. Micro/nanomaterial‐based systems, which leverage the unique properties of miniature materials, are currently well positioned to expand beyond rudimentary biomarker detection toward multiomics signature analysis. To enable clinical translation, the rational design and implementation of miniaturized systems should be driven by the unique clinical challenges present at various crucial cancer stages. This review features micro/nanomaterial‐based systems that are robustly tested on real patient samples for molecular biomarker detection at i) initial cancer screening and/or diagnosis, ii) cancer prognosis and risk stratification, and iii) longitudinal treatment/recurrence monitoring. Furthermore, this review discusses the use of micro/nanomaterials to facilitate sample preparation for different molecular biomarker species. Finally, this review deliberates on the recent paradigm shift of micro/nanomaterial‐based system innovation toward integrated multiomics cancer signature analysis and puts forth insights and perspectives on existing challenges. It is anticipated that this review could stimulate the propagation of new concepts and approaches to kick‐start a new generation of clinically translational technologies that capitalize on multiomics cancer signatures.